Inmune Bio Inc. claimed a phase II win with TNF inhibitor Xpro (pegipanermin) in early Alzheimer’s disease (AD), though the ...

The IPO market for med-tech companies continues to set new records. With one IPO closed the last week of June, two slated for ...

Abvance Therapeutics Inc. secured an undisclosed amount of capital in a seed round led by Zubi Capital to support development of an insulin and glucagon combination product that the company has been ...

T-cell activity is often suppressed by the immunosuppressive nature of the tumor microenvironment, contributing to the ...

CDR-Life Inc. has announced CDR-609 as its next clinical candidate. Built on the company’s proprietary M-gager platform, ...

Abion Inc. signed a potential $1.315 billion deal with an anonymous partner June 22, granting the counterparty exclusive ...

B4, to its pipeline for prevention of group A Streptococcus (GAS) infections. Invasive GAS infections can cause diseases such ...

At the 11th Congress of the European Academy of Neurology, which was held in Helsinki June 21 to June 24, researchers ...

Atai Therapeutics Inc. has patented new 5-HT2A receptor agonists reported to be useful for the treatment of substance abuse and dependence, treatment-resistant depression, major depression, anxiety, ...

Novo Nordisk A/S recently presented data regarding their antibody fragment Inno-8 for the potential treatment of hemophilia A ...

Aprea Therapeutics Inc. has announced new preclinical data on APR-1051, the company’s next-generation oral WEE1 inhibitor, in ...

With a growing number of people wearing continuous glucose monitors and an ever-shrinking number of hospital-based nurses, ...